Acute myeloid leukemia (AML) carrying nucleophosmin (NPM1) mutations and cytoplasmic NPM (NPMc+ AML) accounts for about one-third of all AML patients, and exhibits distinctive biological and clinical features. The role of NPM1 mutations in leukemogenesis remains elusive. Mathematical models have been developed that, starting from cancer incidence data, allow to infer the somatic mutation rate, or the number of genetic events required to cause cancer. We collected data on age at diagnosis of AML patients from four centers in three different countries, and calculated age-specific rates of NPMc+ AML. A total of 4,155 AML patients were investigated. NPM1 mutations these were detected in 1288. Patients carrying NPM1 mutations with age below 20 years and above 59 years were excluded from the study because of the low number of younger cases and because older patients are not always referred to major institutions for diagnosis and treatment. To investigate NPMc+ AML we adapted one-mutation model published by Michor et al (
Disclosure: No relevant conflicts of interest to declare.